A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
Study Status
Open to Enrollment
Study Description
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy plus ipilimumab live longer that those treated with radiotherapy alone.
Disease Status and/or Stage
Castration-Resistant Prostate Cancer
Sponsor
Bristol-Myers Squibb
Key Eligibility
- Men age 18 and older
- Advanced prostate cancer
- At least 1 bone metastasis
- Prior treatment with docetaxel
- Additional eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- Gina Mileo, RN
- (212) 746-5430
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
